Corvus Pharmaceuticals (CRVS) vs Latigo Biotherapeutics (LTGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Latigo Biotherapeutics is the larger company by market cap ($861.9 million vs $815.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | LTGO |
|---|---|---|
| Share price | $9.67 | $13.00 |
| Market cap | $815.69M | $861.89M |
| 1-day change | -3.40% | -1.81% |
| YTD return | +25.58% | — |
| 1-year return | +12.84% | — |
| 5-year return | +183.58% | — |
| EPS (TTM) | $-0.72 | $-6.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-15.28M | — |
| 52-week high | $26.95 | $25.93 |
| 52-week low | $6.39 | $10.24 |
| Distance from 52-week high | -64.12% | -49.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +225.75% | +301.92% |
| Average volume | 1.05M | 309.60K |
| Shares outstanding | 84.35M | 66.30M |
| Employees | 37 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
CRVS vs LTGO FAQ
Which is bigger, Corvus Pharmaceuticals or Latigo Biotherapeutics?
Latigo Biotherapeutics (LTGO) is larger, with a market capitalization of $861.89M compared with $815.69M for Corvus Pharmaceuticals (CRVS).
Are Corvus Pharmaceuticals and Latigo Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.